• How ATRA Re-sensitized Ovarian Cancer to Niraparib

  2026-10-14

  A 2025 Molecular Cancer Therapeutics study examined why cisplatin-treated epithelial ovarian cancer models became less responsive to niraparib and whether all-trans retinoic acid could reverse that state. The reported data connected resistance with increased ALDH1A1, NAMPT, PARP1, checkpoint kinase 1, and intracellular NAD+, while ATRA reduced these features and improved niraparib-associated growth suppression and survival in mouse models. The findings are mechanistically suggestive but remain preclinical and do not establish clinical efficacy, BRCA dependence, or equivalence among commercial niraparib formulations.

• FKBP11 at the ER Translocon: Evidence and Limits

  2026-10-14

  A 2024 Molecular Biology of the Cell study proposes that FKBP11 is an accessory factor at ER ribosome–translocon complexes. Its binding, transcript-level association patterns, and effects on selected protein stabilities support the model, but the evidence does not yet establish a universal substrate range or direct catalytic mechanism. The 3X (DYKDDDDK) Peptide is a separate epitope-tagging reagent whose supplier-described applications should not be conflated with the FKBP11 findings.

• TBXA2R–ERM Signaling in TNBC Metastasis

  2026-10-13

  Leguay et al. report that the thromboxane A2 receptor, TBXA2R, activates ERM cytoskeletal regulators through Gαq/11, Gα12/13, Rho GTPases, and the kinases SLK and LOK, thereby promoting motility, invasion, and metastatic colonization in triple-negative breast cancer models. The findings define a preclinical signaling mechanism, but they do not establish a clinical therapy or connect the pathway to Tetrahydromagnolol, CB2, or GPR55 pharmacology.

• PPM-18: Evidence, Scope, and Key Limits

  2026-10-13

  PPM-18 is a chemically synthesized naphthoquinone derivative described by its supplier as an inhibitor of NF-κB-linked iNOS expression. The available information supports a conceptual role in inflammation and immune response modulation and sepsis research, but it does not establish clinical efficacy or demonstrate relevance to the oridonin bone study.

• Metronidazole: Evidence, Scope, and Boundaries

  2026-10-12

  Metronidazole, or 2-(2-methyl-5-nitroimidazol-1-yl)ethanol, has a documented nitroimidazole identity and a vendor-described research scope involving anaerobic bacteria, protozoa, and organic anion transport. The supplied peer-reviewed reference concerns a different antibiotic combination, so it cannot substantiate metronidazole-specific biological or translational claims.

• Afatinib and Gastric Cancer Assembloid Evidence

  2026-10-12

  A source-grounded overview of a 2025 patient-derived gastric cancer assembloid study, its reported tumor–stroma findings, and the limited evidence connecting Afatinib or BIBW 2992 to this model.

• 3X FLAG Peptide and TXNL1 Proteasome Research

  2026-10-11

  The reported TXNL1–proteasome study provides structural evidence for a ubiquitin-independent interaction and stress-associated degradation mechanism. It does not establish the performance or use of the 3X (DYKDDDDK) Peptide, which is described separately by APExBIO as an epitope-tag reagent.

• Ceapin-A7 and ATF6α in Bone Stress Research

  2026-10-10

  Ceapin-A7 is a selective ER stress blocker that can help separate ATF6α signaling from the PTX3–TLR4/NF-κB–FGF21 biology reported in glucocorticoid-induced osteonecrosis. This article develops a non-operational framework for interpreting pathway relationships, evidence strength, and research boundaries.

• Mitoguardin-2 Lipid Transfer and Organelle Homeostasis

  2026-10-09

  Hong et al. identify mitoguardin-2 (MIGA2) as a mitochondrial lipid-transfer protein whose C-terminal domain contains a hydrophobic lipid-binding cavity. Structural, biochemical, and cellular evidence connects MIGA2-mediated lipid movement with mitochondrial morphology and lipid droplet formation, while leaving the precise contribution of mitochondria–lipid droplet contacts to be resolved.

• Cimetidine at the BBB: From H2 Biology to Translation

  2026-10-09

  Cimetidine offers a useful case study in how receptor pharmacology, barrier transport, and translational evidence should be interpreted together. This article connects H2 receptor biology with a 2025 surrogate BBB model while defining what the available evidence does—and does not—support.

• Mitoguardin-2 Lipid Transfer and Organelle Health

  2026-10-08

  Hong et al. identify mitoguardin-2 (MIGA2) as a lipid-transfer protein whose C-terminal domain contains a hydrophobic lipid-binding cavity. Structural, biochemical, and cell-based evidence connects this activity with mitochondrial morphology and lipid-droplet formation, while also defining important limits on what the study establishes about lipid transport in living cells.

• Praeruptorin A: Reading Multitarget Evidence

  2026-10-08

  Praeruptorin A is an angular pyranocoumarin compound with reported activity across ferroptosis, inflammation, barrier biology, cardiomyopathy research, and tumor-cell migration. This evidence-focused review separates supplier-described mechanisms from peer-reviewed findings and explains how to interpret its translational potential without overstating the data.

• Diuron-Induced Acute Kidney Injury: JAK2/STAT1 Insights

  2026-10-07

  A 2025 study integrates network toxicology, transcriptomic validation, molecular docking, and HK-2 cell experiments to investigate how Diuron may contribute to acute kidney injury. Its findings prioritize JAK2/STAT1 signaling as a mechanistic hypothesis for environmental toxicology and provide a framework for interpreting pesticide-associated nephrotoxicity, while leaving important questions about causality, exposure relevance, and in vivo transferability unresolved.

• 20-HETE–TRPV1 Signaling in Chronic Dermatitis

  2026-10-07

  A 2024 Theranostics study identifies a peripheral mechanism linking elevated 20-HETE to TRPV1 activation and itch-pain sensory switching in chronic dermatitis. Using complementary mouse models, neuronal recordings, metabolomics, and human and mouse skin measurements, the authors position sensitized MrgprA3+ neurons as a key cellular substrate for allokinesis while highlighting important limits on therapeutic translation.

• Hoechst 33342 and Sodium-Driven Cell Death

  2026-10-06

  Hoechst 33342 is more than a nuclear label in studies of sodium-driven injury: it provides a morphological readout of chromatin and nuclear fate. This article connects its capabilities to the NECSO mechanism reported by Qiao et al. while defining what nuclear fluorescence can—and cannot—prove.

8580 records 1/572 page Next 12345 下5页 Last page